Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FJ3HS
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,703
Award facts
- Contract value 100% obligated
- $27,703.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $27,703.32 delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and identifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026.
AmerisourceBergen's role as a prime contractor under the DLA Troop Support Medical IDC positions the company as a critical supplier for the Defense Health Agency and broader military healthcare systems. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a diverse range of pharmaceutical products, vaccines, and medical supplies across multiple therapeutic domains. This Dupixent delivery order represents one of numerous pharmaceutical procurements fulfilled through the contract vehicle, supporting the military healthcare system's need for specialty medications including immunology treatments such as Dupixent, which is utilized for eczema, asthma, and other inflammatory conditions in military personnel.
Quick answers
Who was awarded contract SPE2DB25FJ3HS?
SPE2DB25FJ3HS was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 25, 2025.
How much is contract SPE2DB25FJ3HS worth?
The government has obligated $27,703 on SPE2DB25FJ3HS.
Is contract SPE2DB25FJ3HS an order under another contract?
Yes. SPE2DB25FJ3HS is a delivery order under SPE2DB22D2007, an indefinite delivery contract.
Was contract SPE2DB25FJ3HS competed?
The extent of competition for SPE2DB25FJ3HS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award